Article
MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.
Leukemia & lymphoma - 1 Jun 2018
Raess Philipp W, Moore Stephen R, Cascio Michael J, Dunlap Jennifer, Fan Guang, Gatter Ken, Olson Susan B, Braziel Rita M
Abstract excerpt
Accurate subclassification of aggressive B cell lymphomas (ABCLs) requires integration of morphologic, immunohistochemical (IHC), and cytogenetic information. Optimal strategies have not been well defined for diagnosis of high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBLwR) and double expressor lymphomas with MYC and BCL2 protein overexpression. One hundred and eighty seven ABCLs were...
Topics
- Biomarkers, Tumor
- Cytogenetic Analysis
- Gene Expression
- Genetic Variation
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Ki-67 Antigen
- Lymphoma, B-Cell
- Neoplasm Grading
